Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024
July 09, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes
July 01, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
May 29, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), or Achieve, a late-stage pharmaceutical company committed to the global...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
May 17, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
May 09, 2024 16:01 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company dedicated to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
May 06, 2024 11:16 ET | Achieve Life Sciences
Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo   Cytisinicline treatment well tolerated with no serious adverse events...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
April 25, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
April 11, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
March 28, 2024 16:01 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and...
Achieve_Life_Sciences_Logo.jpg
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
March 20, 2024 08:00 ET | Achieve Life Sciences
SEATTLE and VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...